共 14 条
[1]
The development of hirudin as anantithrombotic drug. Markwardt F. Thrombosis Research . 1994
[2]
Chimericantithrombin peptide.Characterization of an Arg-Gly-Asp (RGD)-and hirudin carboxyl terminus-containing synthetic peptide. Church FC,Phillips JE and Woods JL. Journal of Biological Chemistry . 1991
[3]
Synthesisof a homologous series of ketomethylene arginylpseudodipeptides and application to low molecularweight hirudin-like thrombin inhibitors. DiMaio J,Gibbs B,Lefebvre J,et al. Journal of Medicinal Chemistry . 1992
[4]
Interac-tion of hirudin with thrombin: identification of aminimal binding domain of hirudin that inhibitsclotting activity. Mao SJT,Yates MT,Owen TJ,et al. Biochemistry . 1988
[5]
Inhibition of in vitro clotgrowth by r-hirudin is more effective and longersustained than by an analogous peptide. Romisch J,Stohr H-A. Thrombosis and Haemostasis . 1994
[6]
Design and characterization of hirulogs: a novelclass of bivalent peptide inhibitors of thrombin. Maraganore JM,Bourdon P,Jablonski J,et al. Biochemistry . 1990
[7]
Thecomplete amino acid sequence of hirudin, athrombin specific inhibitor. Dodt J,Muller HP,Seemuller U,et al. FEBS Letters . 1984
[8]
Hirudin C-terminal fragments inhibit thrombin induced neu-trophil chemotaxis. Rowand JK,Marucha P,Berliner LJ. Thrombosis and Haemostasis . 1992
[9]
Antithrombotic effects of synthetic peptidei tar-geting various functional domains of thrombin. Kelly AB,Maraganore JM,pourdon P,et al. Proceedings of the National Academy of Sciences of the United States of America . 1992
[10]
Antith-rombin activity of the hirudin N-terminal core do-main residues 1-43. Chang J-Y,Schlaeppi J-M,Stone SR. FEBS Letters . 1990